1. Home
  2. GROV vs ACRV Comparison

GROV vs ACRV Comparison

Compare GROV & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

HOLD

Current Price

$1.34

Market Cap

58.4M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.67

Market Cap

47.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROV
ACRV
Founded
2016
2018
Country
United States
United States
Employees
415
N/A
Industry
Package Goods/Cosmetics
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.4M
47.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GROV
ACRV
Price
$1.34
$1.67
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$1.60
$13.00
AVG Volume (30 Days)
75.4K
864.7K
Earning Date
03-05-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.81
$691.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$1.05
52 Week High
$1.66
$5.65

Technical Indicators

Market Signals
Indicator
GROV
ACRV
Relative Strength Index (RSI) 50.56 49.01
Support Level $1.29 $1.49
Resistance Level $1.46 $1.86
Average True Range (ATR) 0.07 0.11
MACD 0.00 0.02
Stochastic Oscillator 70.59 66.18

Price Performance

Historical Comparison
GROV
ACRV

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: